NASDAQ:CLRB - Cellectar Biosciences Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $4.25
  • Forecasted Upside: 245.53 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$1.23
▲ +0.01 (0.82%)

This chart shows the closing price for CLRB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cellectar Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CLRB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CLRB

Analyst Price Target is $4.25
▲ +245.53% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Cellectar Biosciences in the last 3 months. The average price target is $4.25, with a high forecast of $5.50 and a low forecast of $3.00. The average price target represents a 245.53% upside from the last price of $1.23.

This chart shows the closing price for CLRB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 investment analysts is to buy stock in Cellectar Biosciences. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/1/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/31/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/29/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/27/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/26/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/26/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/25/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/24/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/7/2021HC WainwrightReiterated RatingBuy$3.00Medium
4/25/2021OppenheimerReiterated RatingBuy$5.50Medium
3/2/2021Roth CapitalReiterated RatingBuyHigh
8/11/2020HC WainwrightReiterated RatingBuy$3.00Low
7/1/2020OppenheimerInitiated CoverageOutperform$5.00High
6/23/2020Maxim GroupInitiated CoverageBuy$3.00High
3/10/2020HC WainwrightReiterated RatingBuy$3.00Medium
1/21/2020Roth CapitalReiterated RatingBuy$10.00Low
12/10/2019HC WainwrightReiterated RatingBuy$3.00High
11/13/2019HC WainwrightReiterated RatingBuy$3.00Low
10/1/2019Roth CapitalInitiated CoverageBuy$11.00Medium
9/13/2019Roth CapitalInitiated CoverageBuy$11.00High
8/16/2019HC WainwrightSet Price TargetBuy$3.00Medium
7/29/2019Brookline Capital ManagementInitiated CoverageBuy$6.00 ➝ $6.00High
5/2/2019HC WainwrightInitiated CoverageBuy$4.00High
11/20/2018Brookline Capital ManagementReiterated RatingBuyLow
12/21/2016LADENBURG THALM/SH SHInitiated CoverageBuy$27.00N/A
12/21/2016Langenberg & CompanyInitiated CoverageBuy$27.00N/A
(Data available from 6/24/2016 forward)
Cellectar Biosciences logo
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131, which is in Phase II clinical study in patients with relapsed or refractory (R/R) Waldenstrom's macroglobulinemia (WM) and B-cell malignancies; and Phase IIB clinical study in r/r multiple myeloma (MM) patients, as well as Phase I study for various pediatric cancers, R/R head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in preclinical stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; and Orano Med to develop CLR 12120 Series. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.
Read More

Today's Range

Now: $1.23
Low: $1.21
High: $1.25

50 Day Range

MA: $1.46
Low: $1.18
High: $1.82

52 Week Range

Now: $1.23
Low: $1.01
High: $2.98

Volume

663,288 shs

Average Volume

1,282,861 shs

Market Capitalization

$64.85 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.63

Frequently Asked Questions

What sell-side analysts currently cover shares of Cellectar Biosciences?

The following Wall Street analysts have issued reports on Cellectar Biosciences in the last year: HC Wainwright, Oppenheimer Holdings Inc., Roth Capital, and Zacks Investment Research.
View the latest analyst ratings for CLRB.

What is the current price target for Cellectar Biosciences?

2 Wall Street analysts have set twelve-month price targets for Cellectar Biosciences in the last year. Their average twelve-month price target is $4.25, suggesting a possible upside of 245.5%. Oppenheimer Holdings Inc. has the highest price target set, predicting CLRB will reach $5.50 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $3.00 for Cellectar Biosciences in the next year.
View the latest price targets for CLRB.

What is the current consensus analyst rating for Cellectar Biosciences?

Cellectar Biosciences currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CLRB will outperform the market and that investors should add to their positions of Cellectar Biosciences.
View the latest ratings for CLRB.

What other companies compete with Cellectar Biosciences?

How do I contact Cellectar Biosciences' investor relations team?

Cellectar Biosciences' physical mailing address is 100 CAMPUS DRIVE, FLORHAM PARK NJ, 07932. The biopharmaceutical company's listed phone number is 608-441-8120 and its investor relations email address is [email protected] The official website for Cellectar Biosciences is www.cellectar.com.